An Open-label, Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia, High-Risk Myelodysplastic Syndrome or T Acute Lymphoblastic Leukemia/Lymphoma
The goal of this clinical research study is to learn if daratumumab can help to control acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that is refractory (does not respond to treatment) or relapsed (comes back after being treated). The safety of this drug will also be studied.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Daratumumab
Treatment Location: Only at MD Anderson
Sponsor: Janssen Scientific Affairs, LLC is the Supporter of this study.
IRB Review and Approval Date: 10/27/2017
Recruitment Status: Open
Projected Accrual: N/A
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: